A study by healthcare consultants Medical Options of London estimated that 491,000 patient studies will be performed using PET in Western Europe in 2006.
The 36% increase compares with 361,000 patient studies performed in 2005. Research studies comprise 6% the total patient studies.
The report also noted that the use of fluorinated compounds, other than FDG, in routine clinical use is increasing. Fluorocholine for patients with suspected prostate cancer is the most popular, the report said.
In addition, PET/CT scanners now comprise 57% of installed PET and PET/CT systems in Western Europe.
By AuntMinnie.com staff writers
January 22, 2007
Related Reading
New growth for diagnostic radiopharmaceuticals, November 9, 2006
Radiopharma market expected to double by 2012, October 10, 2006
New promise for diagnostic radiopharmaceuticals, June 2, 2006
Therapeutic radiopharmaceutical market poised for takeoff, February 21, 2006
FDA issues draft CGMP for PET radiopharmaceuticals, September 26, 2005
Copyright © 2007 AuntMinnie.com
